Zai Lab Q3 Revenue Slips 7% as Inventory Write-Down Widens Net Loss to $46.1M
ZLAB sits 45% above its 52-week low of $15.96.
Summary
Q3 total revenue fell to $108.2 million from $116.1 million a year ago, with product revenue down 7% as reported and 11% at constant currency. Net loss widened to $46.1 million, or $0.41 per ADS, from $36.0 million, largely because of $13.6 million in inventory write-downs. Cash, restricted cash and short-term investments stood at $659.7 million on September 30, down from $717.5 million at June 30, and the $250 million private placement closed October 27 adds roughly $241.2 million net. The pipeline is the offset: zoci plus atezolizumab showed an 81.8% confirmed response rate in first-line small cell lung cancer, the company plans to start a global Phase 3 in that setting by year-end 2026, and FDA feedback supports an accelerated approval path in extrapulmonary neuroendocrine carcinomas with topline data in the first half of 2027. On the downside, partner argenx is discontinuing the Phase 3 UNITY study of subcutaneous efgartigimod in Sjögren's disease for futility. Management expects the China commercial business to return to growth in 2027 and is targeting a potential first U.S. BLA for zoci that year; the 8:00 a.m. ET call today will carry the guidance detail.
At the time of this announcement, ZLAB was trading at $23.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $15.96 to $27.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.